Greenwood, INNCT07265947Now EnrollingIRB Ready

Low Grade Upper Tract Urothelial Carcinoma Clinical Trial in Greenwood, IN

Access cutting-edge low grade upper tract urothelial carcinoma treatment through this clinical trial at a research site in Greenwood. Study-provided care at no cost to qualified participants.

Sponsored by Tyra Biosciences, Inc

Quick Self-Assessment

See if you qualify for this Greenwood location

Preparing your pre-screening questions…

Expert Care in Greenwood

Access low grade upper tract urothelial carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related low grade upper tract urothelial carcinoma treatment provided free

Apply for This Greenwood Location

Check if you qualify for this low grade upper tract urothelial carcinoma clinical trial in Greenwood, IN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Greenwood

    Convenient for IN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Greenwood site if eligible
  4. 4Begin participation

About This Low Grade Upper Tract Urothelial Carcinoma Study in Greenwood

A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma

Sponsor: Tyra Biosciences, Inc

Who Can Participate

Inclusion Criteria

Criterion #2)
If synchronous NMIBC, NMIBC must be fully resected and low-grade Ta or T1
No prior BCG administration within 1 year of date of consent.
No intravesical chemotherapy within 8 weeks prior to C1D1 (including UGN-101).
No systemic chemotherapy within 3 months prior to C1D1
Pathology consists of pure urothelial carcinoma
Adequate bone marrow, liver, and renal function:
i. Absolute neutrophil count (ANC) ≥1,500/mm3 ii. Platelet count ≥75,000/mm3 iii. Hemoglobin ≥10.0 g/dL
i. Total bilirubin ≤ ULN ii. Alanine aminotransferase (ALT) ≤ ULN iii. Aspartate aminotransferase (AST) ≤ ULN
Estimated glomerular filtration rate \>60 mL/min
Serum Phosphate level ≤ ULN prior to starting treatment
International normalized ratio (INR) ≤1.5 × ULN

Exclusion Criteria

Evidence or any features of high grade (HG) UTUC
History of carcinoma in situ (CIS)
History of prostatic urethral involvement
Current or previous history of muscle invasive bladder cancer
Current or previous history of lymph node positive and/or metastatic bladder cancer
Evidence of squamous cell carcinoma, adenocarcinoma or undifferentiated carcinoma or small cell of the bladder
Currently receiving systemic cancer therapy (cytotoxic or immunotherapy)
Current or prior history of pelvic external beam radiotherapy for bladder cancer
Current or history of receiving a prior FGFR inhibitor
Systemic immunotherapy within 6 months prior to randomization
Treatment with an investigational agent within 30 days or 5 half-lives from randomization, whichever is shorter; compounds with an unknown half-life will be default to 30 days.
Prior treatment with an intravesical or intracavitary agent within 8 weeks of C1D1.
Current evidence of central serous retinopathy or retinal pigmented epithelial detachment of any grade at time of baseline examination.
Requiring use of medications that are potential inhibitors or inducers of CYP3A (prohibited list of medications)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Greenwood?

Yes, this clinical trial (NCT07265947) has an active research site in Greenwood, IN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Low Grade Upper Tract Urothelial Carcinoma Treatment Options in Greenwood, IN

If you're searching for low grade upper tract urothelial carcinoma treatment options in Greenwood, IN, this clinical trial (NCT07265947) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Greenwood research site is actively enrolling participants for this clinical trial. You'll receive care from experienced low grade upper tract urothelial carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all low grade upper tract urothelial carcinoma clinical trials near you to find additional studies recruiting in your area.

More Bladder Cancer Trials in Greenwood, IN

See all bladder cancer clinical trials recruiting in Greenwood — not just this study.

Browse Bladder Cancer Trials in Greenwood →

Browse More Trials by Condition

Bladder Cancer TrialsPulmonary Embolism TrialsAlzheimers Disease TrialsRheumatoid Arthritis TrialsAtopic Dermatitis TrialsAll Conditions →

Ready to Join in Greenwood?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Greenwood, IN